Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This report documents a case where a man survived sub-acute toxicity from an overdose of the anticancer drug UFT due to effective treatment with antibiotics and granulocyte colony-stimulating factor.

S-1 treatment led to a complete response in pancreatic cancer with manageable side effects.

This study explores the design of responsive drug carriers based on the tumor microenvironment to improve targeting and reduce side effects in cancer treatment, using a model of delivering curcumin with a responsive polymer carrier and evaluating potential errors due to cancer cell heterogeneity.

This study suggests that increased use of anticancer drugs from 2004 to 2008 has led to higher environmental release, necessitating expanded monitoring and research on their ecotoxicological impacts.

This review elaborates on the skin side effects of chemotherapy and emphasizes identifying and managing both common and life-threatening skin reactions, without presenting new clinical findings.

This review discusses the various common, rare, and unusual skin manifestations of lupus erythematosus and highlights the importance of accurate diagnosis, but it reports no new clinical results.

This review discusses the pathogenesis, clinical presentation, diagnosis, and treatment of cutaneous lupus erythematosus, reporting no new clinical findings.

This review describes the variety of mucocutaneous side effects caused by antineoplastic chemotherapy, with emphasis on skin, nails, and mucous membranes, while highlighting potential severity and the possibility of needing to adjust or interrupt treatment in rare cases; it presents no new clinical results.

This article reviews drug-induced pigmentation and reports no new clinical findings, highlighting difficulty in confirming drug associations due to factors like delayed onset and polypharmacy.

This review discusses the cutaneous side effects of chemotherapy, noting that they frequently involve changes to skin, hair, and nails, and reports no new results.

This article reviews the dermatological side effects of chemotherapy, their impact on treatment and patient quality of life, and emphasizes collaboration between oncologists and dermatologists for effective management.

In this report, five female patients undergoing hormonal anticancer therapy for breast cancer prevention developed pattern alopecia, which the authors attribute to androgen-estrogen imbalance caused by antiestrogenic drugs.

This article discusses the range of skin-related side effects caused by chemotherapy and radiotherapy, including novel patterns emerging with targeted therapies, but does not report new clinical results.

This review discusses approaches to diagnosing and managing cutaneous manifestations of lupus erythematosus and reports no new clinical results.

In this report, the author shares experiences from a six-month curricular internship, highlighting activities such as arterial pressure monitoring in a community pharmacy and addressing off-label rituximab use at a hospital, alongside discussions of hair loss treatments and nutritional supplementation for dysphagia in the elderly.

This chapter reviews studies on the side effects of cytostatics and immunosuppressive drugs, detailing various toxicities such as cardiovascular, pulmonary, and neurotoxicity, but provides no new clinical results.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.

In this study, inactivating the TAF4 subunit of transcription factor TFIID in mouse epidermis disrupted gene expression linked to skin and hair function, and increased tumor risk.

In this study, tofacitinib showed promising efficacy and safety for biologic-naïve elderly patients with moderate-to-severe ulcerative colitis, achieving steroid-free remission and clinical response over 52 weeks.

In this study, researchers observed no significant association between hijab use and telogen effluvium among female medical students, despite a relatively high incidence of hair loss in this population.

This study suggests that TGF-alpha may function in an autocrine or juxtacrine manner rather than promoting cell proliferation during hair growth cycles in ferrets and sheep.

In this study, oral tofacitinib significantly reduced alopecia severity in pediatric patients with moderate-to-severe alopecia areata over 24 weeks, with 42.2% achieving complete or near-complete hair regrowth, although further research is needed on long-term safety and relapse rates.

This study in Mexican adolescents with severe alopecia areata reported that oral tofacitinib treatment resulted in hair growth and reduced alopecia severity without serious adverse effects.

In this case report, a young adult male with resistant alopecia areata showed nearly 90% hair regrowth after 3 months of treatment with tofacitinib, alongside biotin supplementation, without any side effects observed.

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

This study found that combining celecoxib with chemotherapy improved overall survival, disease-free survival, and quality of life in gastric cancer patients with positive COX-2 expression without increasing adverse events.

This manuscript explores the development and future potential of injectable biomimetic gels in biomedical applications, highlighting their promise in wound healing and tissue regeneration, while also acknowledging challenges like mechanical durability and scalable production still persist.

This retrospective study found a variety of dermatological adverse events associated with antineoplastic treatments, often leading to changes or suspension of cancer therapies in affected patients.

In this study, induction nab-paclitaxel plus cisplatin, combined with nimotuzumab and IMRT, followed by S-1 adjuvant chemotherapy, showed excellent survival benefits with tolerable toxicities for stage N3 nasopharyngeal carcinoma patients.

This review highlights the significant impact of cutaneous and oral mucosal adverse events on patients undergoing breast cancer treatment, emphasizing the need for early detection and comprehensive management to maintain treatment adherence and enhance patient care.